HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incidence, determinants and clinical impact of left ventricular function recovery after surgical treatments for ischaemic cardiomyopathy.

AbstractOBJECTIVES:
This retrospective study aimed to clarify the incidence, determinants and clinical impact of left ventricular (LV) function non-recovery after coronary artery bypass grafting (CABG) in patients with ischaemic cardiomyopathy.
METHODS:
A total of 490 patients with ischaemic cardiomyopathy (LV ejection fraction ≤ 40%) undergoing CABG were analysed. Follow-up echocardiography was performed at 1 month, 1 year, and annually thereafter. LV function recovery was defined as ejection fraction (EF) ≥40% at least once during follow-up. LV function non-recovery was defined as EF <40% at any follow-up. The primary and secondary end points were changes in LV function and all-cause mortality, respectively. Clinical follow-up was completed in 461 patients (94.1%; mean follow-up: 64.5 ± 45.5 months).
RESULTS:
During follow-up, echocardiographic assessments were performed 1863 times (mean, 3.8 ± 2.4), and 193 patients (39.4%) exhibiting LV function non-recovery were identified. Overall survival was significantly higher in the recovery group (53.9%) than in the non-recovery group (31.4%) at 10 years (P < 0.001). Independent predictors of LV function non-recovery were preoperative LV end-systolic diameter [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04-1.10; P < 0.001] and bilateral internal thoracic artery grafting (OR 0.61, 95% CI 0.39-0.95; P = 0.028). In a multivariable Cox proportional hazards model, LV function non-recovery was significantly associated with all-cause mortality (hazard ratio 2.14, 95% CI 1.60-2.86; P < 0.001).
CONCLUSIONS:
Almost 40% of patients with ischaemic cardiomyopathy undergoing CABG did not achieve LV function recovery and were associated with poor prognosis. To achieve LV function recovery, CABG with bilateral internal thoracic artery may be recommended before excessive LV remodelling occurs.
CLINICAL TRIAL REGISTRATION NUMBER:
Institutional review board of Osaka University Hospital, number 16105.
AuthorsMasaro Nakae, Satoshi Kainuma, Koichi Toda, Shigeru Miyagawa, Yasushi Yoshikawa, Hiroki Hata, Daisuke Yoshioka, Takuji Kawamura, Ai Kawamura, Noriyuki Kashiyama, Sho Komukai, Tetsuhisa Kitamura, Atsushi Hirayama, Takayoshi Ueno, Toru Kuratani, Haruhiko Kondoh, Takafumi Masai, Arudo Hiraoka, Taichi Sakaguchi, Hidenori Yoshitaka, Yukitoshi Shirakawa, Toshiki Takahashi, Kazuhiro Taniguchi, Yoshiki Sawa, Osaka Cardiovascular Surgery Research (OSCAR) Group
JournalEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (Eur J Cardiothorac Surg) Vol. 60 Issue 3 Pg. 689-696 (09 11 2021) ISSN: 1873-734X [Electronic] Germany
PMID33779701 (Publication Type: Journal Article)
Copyright© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
Topics
  • Cardiomyopathies (epidemiology, surgery)
  • Follow-Up Studies
  • Humans
  • Incidence
  • Retrospective Studies
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Dysfunction, Left (epidemiology, surgery)
  • Ventricular Function, Left

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: